IL-1beta Stimulation of 3D Epidermal Models for Atopic Dermatitis Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro models for atopic dermatitis (AD) are inadequate as they do not accurately replicate the molecular and structural characteristics of the disease, particularly the skin barrier function, and are limited in their ability to screen active principles for treatment or repair of the skin barrier.
Innovation Solution
A three-dimensional epidermal model is developed by stimulating a skin substitute with a pro-inflammatory reagent containing IL-1β, which induces the production of key molecular mediators and modulates skin barrier function, allowing for the reproducible induction of AD markers such as TSLP, RANTES/CCL5, MCP-3/CCL7, IL-6, and IL-8, and the degradation of ultrastructural markers indicative of skin barrier integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If monolayer keratinocyte culture models are used, then cell proliferation and undifferentiated state are maintained, but epidermal differentiation markers are not expressed and skin barrier function is not replicated
Solution Approach 1:
The invention transitions from two-dimensional monolayer culture to three-dimensional reconstructed epidermis models, adding spatial dimensionality that enables proper cell-cell interactions, differentiation gradients, and barrier function formation while maintaining proliferative capacity in the basal layer
Solution Approach 2:
The reconstructed epidermis is organized into distinct layers (basal, spinous, granular, stratum corneum) with segment-specific functions, allowing simultaneous maintenance of proliferation in basal layers and differentiation in upper layers, thereby resolving the contradiction between undifferentiated state and differentiation marker expression
2Adaptability or versatility
If human skin explants are used, then surgical waste availability is constrained, but the model lacks reproducibility for screening active ingredients
Solution Approach 1:
The invention creates standardized in vitro copies of human epidermis using cultured keratinocytes that replicate the structural and functional characteristics of native skin, eliminating variability from surgical waste while maintaining biological relevance for screening applications
Solution Approach 2:
The reconstructed epidermis models use controlled cultivation parameters (cell density, growth factors, differentiation cues) to achieve consistent, reproducible results across multiple experiments and batches, whereas skin explants exhibit donor-to-donor variability that compromises reliability
3Measurement precision
If skin substitutes are stimulated with pro-inflammatory reagents containing IL-1β, then AD pathophysiology is accurately reproduced, but the complexity of the model increases
Solution Approach 1:
The pro-inflammatory stimulation with IL-1β and other reagents is applied as a predefined protocol step to differentiated reconstructed epidermis, allowing the model to transition from a baseline state to an AD-like state in a controlled manner, thereby managing complexity through standardized procedures
Solution Approach 2:
The reconstructed epidermis model serves multiple functions: it can be used in both differentiated and pro-inflammatory states, allowing the same base model to study multiple aspects of skin biology and pathology without requiring separate complex systems for each condition
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention relates to the use of a pro-inflammatory stimulating reagent containing between 10 and 500 ng/mL of interleukin IL-1β to reproduce the physiopathology of atopic dermatitis in vitro and/or to alter the barrier function in a cutaneous substitute or a cutaneous explant. It also relates to a pro-inflammatory stimulating reagent containing: a. Between 10 and 500 ng/mL interleukin IL-1β, and b. Between 3 and 20 µg/mL of a ligand of the TLR-2 receptor, and/or c. Between 3 and 20 µg/mL of a ligand of the TLR-3 receptor.